These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 23006319

  • 1. Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer.
    Hua X, Yu L, Pan W, Huang X, Liao Z, Xian Q, Fang L, Shen H.
    Diagn Pathol; 2012 Sep 24; 7():127. PubMed ID: 23006319
    [Abstract] [Full Text] [Related]

  • 2. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
    Abd El-Maqsoud NM, Osman NA, Abd El-Hamid AM, Fath El-Bab TK, Galal EM.
    Clin Genitourin Cancer; 2016 Apr 24; 14(2):e143-52. PubMed ID: 26794392
    [Abstract] [Full Text] [Related]

  • 3. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
    Miyoshi Y, Yoneyama S, Kawahara T, Hattori Y, Teranishi JI, Ohta JI, Takebayashi S, Yokomizo Y, Hayashi N, Uemura H.
    Urol Int; 2017 Apr 24; 99(4):400-405. PubMed ID: 28609769
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
    Zhang L, Guo F, Gao X, Wu Y.
    Mol Med Rep; 2015 Jul 24; 12(1):1298-304. PubMed ID: 25760033
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers.
    Möller K, Wecker AL, Höflmayer D, Fraune C, Makrypidi-Fraune G, Hube-Magg C, Kluth M, Steurer S, Clauditz TS, Wilczak W, Simon R, Sauter G, Huland H, Heinzer H, Haese A, Schlomm T, Weidemann S, Luebke AM, Minner S, Bernreuther C, Bonk S, Marx A.
    Virchows Arch; 2020 Nov 24; 477(5):625-636. PubMed ID: 32417965
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. GOLPH3 and YB-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
    El-Maqsoud NMRA, Osman NAA, El-Hamid AMA, El-Bab TKF, Galal EM.
    World J Oncol; 2015 Dec 24; 6(6):473-484. PubMed ID: 28983350
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
    Teoh JY, Tsu JH, Yuen SK, Chan SY, Chiu PK, Lee WM, Wong KW, Ho KL, Hou SS, Ng CF, Yiu MK.
    Ann Surg Oncol; 2015 Apr 24; 22(4):1385-91. PubMed ID: 25234025
    [Abstract] [Full Text] [Related]

  • 16. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
    Xu S, Yi XM, Zhou WQ, Cheng W, Ge JP, Zhang ZY.
    Int J Clin Exp Pathol; 2015 Apr 24; 8(11):14335-44. PubMed ID: 26823749
    [Abstract] [Full Text] [Related]

  • 17. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
    Lu LL, Sun J, Lai JJ, Jiang Y, Bai LH, Zhang LD.
    World J Gastroenterol; 2015 Jun 07; 21(21):6649-59. PubMed ID: 26074703
    [Abstract] [Full Text] [Related]

  • 18. L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival.
    Guo X, Xiong L, Zou L, Sun T, Zhang J, Li H, Peng R, Zhao J.
    Diagn Pathol; 2012 Aug 13; 7():96. PubMed ID: 22888955
    [Abstract] [Full Text] [Related]

  • 19. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
    Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun FK, Recker F, Kwiatkowski M.
    Eur Urol; 2015 Oct 13; 68(4):591-7. PubMed ID: 24794075
    [Abstract] [Full Text] [Related]

  • 20. Expression of store-operated channel components in prostate cancer: the prognostic paradox.
    Perrouin Verbe MA, Bruyere F, Rozet F, Vandier C, Fromont G.
    Hum Pathol; 2016 Mar 13; 49():77-82. PubMed ID: 26826413
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.